Bonanno, Silvia http://orcid.org/0000-0002-8823-6821
Zanin, Riccardo
Bello, Luca
Tramacere, Irene
Bozzoni, Virginia
Caumo, Luca
Ferraro, Manfredi
Bortolani, Sara
Sorarù, Gianni
Silvestrini, Mauro
Vacchiano, Veria
Turri, Mara
Tanel, Raffaella
Liguori, Rocco
Coccia, Michela
Mantegazza, Renato Emilio
Mongini, Tiziana
Pegoraro, Elena
Maggi, Lorenzo http://orcid.org/0000-0002-0932-5173
Article History
Received: 7 September 2021
Revised: 15 December 2021
Accepted: 23 December 2021
First Online: 3 January 2022
Declarations
:
: Dr. Bonanno received honoraria for advisory board activities, and compensation for travel and congress participation from Sanofi Genzyme, Biogen and Roche. Dr. Zanin has received funds for travel and congress participation from Biogen. Dr. Tramacere reports no disclosures. Dr. Bello reports speaker honoraria from PTC Therapeutics, participation in advisory boards for PTC Therapeutics and Sarepta Therapeutics, and participation in research sponsored by Santhera Pharmaceuticals. Dr. Bozzoni compensation for congress participations from Biogen and Sanofi Genzyme. Dr. Caumo received compensation for congress participations from Biogen. Dr. Soraru reports no disclosures. Dr. Ferraro reports no disclosures. Dr. Bortolani has received travel grants from Biogen. Dr. Mongini has received compensation for Scientific Board participations from Sanofi Genzyme; for congress participation from Biogen. Prof. Silvestrini has received speaker’s honoraria from ITALFARMACO, PIAM, Boheringer and Novartis Pharmaceuticals. Dr. Coccia has received honoraria for advisory board activities and speaking compensation for congress participations from Biogen and Roche, outside the submitted work. Dr. Vacchiano reports no disclosures. Dr. Liguori has received: Lecture fees from LT3 s.r.l., NICO s.r.l., SUMMEET s.r.l. and GALEN SYMPOSION s.r.o.; fees for consultancy (Advisory Board) from LT3 s.r.l. and PREX s.r.l.; fees for scientific meeting organization from I&C s.r.l.; Chair meeting fees from PLANNING CONGRESSI s.r.l. Dr. Turri reports no disclosures. Dr. Tanel has received compensation for congress participations from Sanofi Genzyme, Biogen and Roche. Dr. Mantegazza received compensation for participating on advisory boards in relation to MG clinical trial design, congress participations and research support in the last 5 years from: Catalyst Pharmaceuticals, Alexion Pharmaceuticals, ARGENX Pharma, Biomarin. Prof. Pegoraro reports personal fees from Sarepta, grants and non-financial support from Santhera, personal fees and non-financial support from PTC Pharmaceuticals, non-financial support from Genzyme, personal fees from Roche, outside the submitted work. Dr. Maggi has received honoraria for speaking and compensation for congress participations from Sanofi Genzyme, Roche and Biogen, outside the submitted work.
: The study involved seven Italian secondary- or tertiary-care centers for SMA and was approved by Ethics Committees at each center (ID: SMADU; approved by the Ethics Committee of Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, the coordinator center, on 10 July 2019).
: Written informed consent was obtained from all participants, according to the Helsinki declaration.
: Not required.